Scleral Thinning After Repeated Intravitreal Injections of Antivascular Endothelial Growth Factor Agents in the Same Quadrant

2015 ◽  
Vol 56 (3) ◽  
pp. 1894 ◽  
Author(s):  
Martin S. Zinkernagel ◽  
Petra Schorno ◽  
Andreas Ebneter ◽  
Sebastian Wolf
Keyword(s):  
Growth Factor ◽  
Intravitreal Injections ◽  
Antivascular Endothelial Growth Factor ◽  
Endothelial Growth Factor

scholarly journals Long-Term Visual Outcomes for a Treat-and-Extend Antivascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration: Up to Seven-Year Follow-Up

2020 ◽  
Vol 2020 ◽  
pp. 1-12 ◽  
Author(s):  
Simon Javidi ◽  
Ali Dirani ◽  
Fares Antaki ◽  
Marc Saab ◽  
Sofiane Rahali ◽  
...  
Keyword(s):  
Growth Factor ◽  
Age Related Macular Degeneration ◽  
Intravitreal Injections ◽  
Anti Vegf ◽  
Age Related ◽  
Antivascular Endothelial Growth Factor ◽  
Endothelial Growth Factor ◽  
Number Of Injections

Purpose. To report long-term visual and anatomical outcomes in eyes with neovascular age-related macular degeneration (nAMD) treated with a treat-and-extend regimen (TER) of intravitreal antivascular endothelial growth factor (anti-VEGF) injections in real-world settings. Methods. Retrospective cohort study of consecutive patients with nAMD treated with a TER of anti-VEGF intravitreal injections by a single retina specialist (GC). Patients with nAMD who had at least one year of follow-up were identified using an electronic database. Best-corrected visual acuity (BCVA), comprehensive ophthalmologic examination, and macular OCT were performed at each visit. Patients received a loading dose of three monthly intravitreal injections and then were treated according to a TER of bevacizumab, ranibizumab, and/or aflibercept. The number of injections, BCVA, and central retinal thickness (CRT) were evaluated during the follow-up period. Results. 180 eyes from 180 patients were included in the study. Mean age was 75 ± 9 (range: 51–96). Mean BCVA was 0.77 ± 0.64 LogMAR at baseline, 0.69 ± 0.58 LogMAR (p=0.0057) after loading phase, 0.64 ± 0.55 LogMAR (p=0.0001) after 6 months of TER, and 0.76 ± 0.71 LogMAR after 6 years of treatment (n = 32 at year 6). CRT decreased significantly after the loading phase (p=0.0002). The mean number of intravitreal injections per year was 7.6 during the first three years of treatment and then decreased to 5.9 during year 4 to 7. Conclusions. This retrospective study of 180 nAMD patients treated with a TER of intravitreal anti-VEGF demonstrates an initial improvement of BCVA after loading phase, followed by long-term visual stabilization for at least six years. These results were obtained with a high number of injections, averaging close to six injections per year during long-term follow-up. In light of the natural evolution of nAMD, these data support the long-term efficacy of this treatment under real-world conditions of heterogeneity of patients and type of anti-VEGF used.

EVALUATION OF SAFETY FOR BILATERAL SAME-DAY INTRAVITREAL INJECTIONS OF ANTIVASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY

Retina ◽  
2009 ◽  
Vol 29 (9) ◽  
pp. 1213-1217 ◽  
Author(s):  
LUIZ H. LIMA ◽  
SANDRINE A. ZWEIFEL ◽  
MICHAEL ENGELBERT ◽  
JOHN A. SORENSON ◽  
JASON S. SLAKTER ◽  
...  
Keyword(s):  
Growth Factor ◽  
Intravitreal Injections ◽  
Antivascular Endothelial Growth Factor ◽  
Factor Therapy ◽  
Growth Factor Therapy ◽  
Endothelial Growth Factor

scholarly journals Safety of bilateral same-day intravitreal injections of anti-vascular endothelial growth factor agents

2017 ◽  
Vol Volume 11 ◽  
pp. 299-302 ◽  
Author(s):  
Miguel Ruão ◽  
María Andreu-Fenoll ◽  
Rosa Dolz-Marco ◽  
Roberto Gallego-Pinazo
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Intravitreal Injections ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor
Sign in / Sign up

Export Citation Format

Share Document